242 related articles for article (PubMed ID: 17035666)
1. Salvinorin A: from natural product to human therapeutics.
Vortherms TA; Roth BL
Mol Interv; 2006 Oct; 6(5):257-65. PubMed ID: 17035666
[TBL] [Abstract][Full Text] [Related]
2. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist.
Roth BL; Baner K; Westkaemper R; Siebert D; Rice KC; Steinberg S; Ernsberger P; Rothman RB
Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11934-9. PubMed ID: 12192085
[TBL] [Abstract][Full Text] [Related]
3. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.
Chavkin C; Sud S; Jin W; Stewart J; Zjawiony JK; Siebert DJ; Toth BA; Hufeisen SJ; Roth BL
J Pharmacol Exp Ther; 2004 Mar; 308(3):1197-203. PubMed ID: 14718611
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological activity of salvinorin A, the major component of Salvia divinorum.
Listos J; Merska A; Fidecka S
Pharmacol Rep; 2011; 63(6):1305-9. PubMed ID: 22358078
[TBL] [Abstract][Full Text] [Related]
5. A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics.
Cruz A; Domingos S; Gallardo E; Martinho A
Phytochemistry; 2017 May; 137():9-14. PubMed ID: 28190678
[TBL] [Abstract][Full Text] [Related]
6. [Salvinorin A and related diterpenes--biological activity and potential therapeutic uses].
Piekielna J; Fichna J; Janecka A
Postepy Biochem; 2012; 58(4):485-91. PubMed ID: 23662442
[TBL] [Abstract][Full Text] [Related]
7. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice.
Capasso R; Borrelli F; Zjawiony J; Kutrzeba L; Aviello G; Sarnelli G; Capasso F; Izzo AA
Neurogastroenterol Motil; 2008 Feb; 20(2):142-8. PubMed ID: 17931335
[TBL] [Abstract][Full Text] [Related]
8. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: semisynthesis of salvinicins A and B and other chemical transformations of salvinorin A.
Harding WW; Schmidt M; Tidgewell K; Kannan P; Holden KG; Gilmour B; Navarro H; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jan; 69(1):107-12. PubMed ID: 16441078
[TBL] [Abstract][Full Text] [Related]
9. New neoclerodane diterpenoids isolated from the leaves of Salvia divinorum and their binding affinities for human kappa opioid receptors.
Lee DY; Ma Z; Liu-Chen LY; Wang Y; Chen Y; Carlezon WA; Cohen B
Bioorg Med Chem; 2005 Oct; 13(19):5635-9. PubMed ID: 16084728
[TBL] [Abstract][Full Text] [Related]
10. Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.
Cunningham CW; Rothman RB; Prisinzano TE
Pharmacol Rev; 2011 Jun; 63(2):316-47. PubMed ID: 21444610
[TBL] [Abstract][Full Text] [Related]
11. Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum.
Valdés LJ; Chang HM; Visger DC; Koreeda M
Org Lett; 2001 Nov; 3(24):3935-7. PubMed ID: 11720573
[TBL] [Abstract][Full Text] [Related]
12. Differential helical orientations among related G protein-coupled receptors provide a novel mechanism for selectivity. Studies with salvinorin A and the kappa-opioid receptor.
Vortherms TA; Mosier PD; Westkaemper RB; Roth BL
J Biol Chem; 2007 Feb; 282(5):3146-56. PubMed ID: 17121830
[TBL] [Abstract][Full Text] [Related]
13. Psychopharmacology of the hallucinogenic sage Salvia divinorum.
Prisinzano TE
Life Sci; 2005 Dec; 78(5):527-31. PubMed ID: 16213533
[TBL] [Abstract][Full Text] [Related]
14. Michael acceptor approach to the design of new salvinorin A-based high affinity ligands for the kappa-opioid receptor.
Polepally PR; Huben K; Vardy E; Setola V; Mosier PD; Roth BL; Zjawiony JK
Eur J Med Chem; 2014 Oct; 85():818-29. PubMed ID: 25193297
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues.
Riley AP; Groer CE; Young D; Ewald AW; Kivell BM; Prisinzano TE
J Med Chem; 2014 Dec; 57(24):10464-75. PubMed ID: 25426797
[TBL] [Abstract][Full Text] [Related]
16. Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues.
Simpson DS; Katavic PL; Lozama A; Harding WW; Parrish D; Deschamps JR; Dersch CM; Partilla JS; Rothman RB; Navarro H; Prisinzano TE
J Med Chem; 2007 Jul; 50(15):3596-603. PubMed ID: 17580847
[TBL] [Abstract][Full Text] [Related]
17. Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Sheffler DJ; Roth BL
Trends Pharmacol Sci; 2003 Mar; 24(3):107-9. PubMed ID: 12628350
[TBL] [Abstract][Full Text] [Related]
18. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum.
Capasso R; Borrelli F; Capasso F; Siebert DJ; Stewart DJ; Zjawiony JK; Izzo AA
Neurogastroenterol Motil; 2006 Jan; 18(1):69-75. PubMed ID: 16371085
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of salvinorin A analogues as opioid receptor probes.
Tidgewell K; Harding WW; Lozama A; Cobb H; Shah K; Kannan P; Dersch CM; Parrish D; Deschamps JR; Rothman RB; Prisinzano TE
J Nat Prod; 2006 Jun; 69(6):914-8. PubMed ID: 16792410
[TBL] [Abstract][Full Text] [Related]
20. Salvia divinorum: from Mazatec medicinal and hallucinogenic plant to emerging recreational drug.
Zawilska JB; Wojcieszak J
Hum Psychopharmacol; 2013 Sep; 28(5):403-12. PubMed ID: 23794315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
